FEMLYV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Femlyv, and what generic alternatives are available?
Femlyv is a drug marketed by Millicent Pr and is included in one NDA.
The generic ingredient in FEMLYV is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FEMLYV?
- What are the global sales for FEMLYV?
- What is Average Wholesale Price for FEMLYV?
Summary for FEMLYV
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | FEMLYV at DailyMed |
US Patents and Regulatory Information for FEMLYV
FEMLYV is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting FEMLYV
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Millicent Pr | FEMLYV | ethinyl estradiol; norethindrone acetate | TABLET, ORALLY DISINTEGRATING;ORAL | 218718-001 | Jul 22, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
